Barely Significant
← all excerpts

<i>SYTL4</i> May Serve as a New Predictive Biomarker for Survival and Trastuzumab Treatment Responsiveness in HER2-Positive Breast Cancer.

Int J Mol Sci · 2026 · PMC13206864 · PMID 42196512

Europe PMCDOI
1
hedged sentence
0.0000
closest p · 0.0× alpha
0.0000
boldest claim

The sentences

highly significantp < 2.2 × 10 −16actually significant
The difference was highly significant ( p < 2.2 × 10 −16 ), indicating robust epigenetic dysregulation of the SYTL4 locus in breast cancer ( Figure 2 A).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.